Randomized Phase II Study of the Safety and Efficacy of Semorinemab in Participants With Mild-to-Moderate Alzheimer Disease: Lauriet

BACKGROUND AND OBJECTIVES: Accumulation of tau pathology in Alzheimer disease (AD) correlates with cognitive decline. Anti-tau immunotherapies were proposed as potential interventions in AD. While antibodies targeting N-terminal tau failed to demonstrate clinical efficacy in prodromal-to-mild AD, th...

Descripción completa

Detalles Bibliográficos
Autores principales: Monteiro, Cecilia, Toth, Balazs, Brunstein, Flavia, Bobbala, Ashwini, Datta, Seema, Ceniceros, Ryan, Sanabria Bohorquez, Sandra M., Anania, Veronica G., Wildsmith, Kristin R., Schauer, Stephen P., Lee, Julie, Dolton, Michael J., Ramakrishnan, Vidya, Abramzon, Daniel, Teng, Edmond
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10573141/
https://www.ncbi.nlm.nih.gov/pubmed/37643887
http://dx.doi.org/10.1212/WNL.0000000000207663

Ejemplares similares

Ejemplares similares